DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1112435
Title:
Repurposing Thymoquinone as Therapy for Metastatic Castration-Resistant Prostate Cancer
Corporate Author:
MOREHOUSE SCHOOL OF MEDICINE ATLANTA GA ATLANTA United States
Report Date:
2020-09-01
Abstract:
The primary goal of this project is to elucidate the mechanism of action of thymoquinone TQ against docetaxel DTX-resistant, metastatic castration-resistant prostate cancer mCRPC. We formulated a novel TQ nanoparticles NPs capable of rapid clinical translation we utilized a highly innovative-patented NP platform, the planetary ball-milling PBM platform. In this study, we investigate whether thymoquinone directly inhibits ABCB1 transporter activity in mCRPC cells. We found that TQ can now bind and inhibit the transporter activity of ABCB1, thereby enhancing the cytotoxicity of DTX in mCRPC cells. We have also identified thymoquinone inhibits the transcription of ABCB1 through a ZEB1-dependent mechanism.
Descriptive Note:
Technical Report,01 Sep 2019,31 Aug 2020
Pages:
0037
Distribution Statement:
Approved For Public Release;
File Size:
5.66MB
